164 related articles for article (PubMed ID: 38890501)
1. Reflections on the discovery GLP-1 as a satiety hormone: Implications for obesity therapy and future directions.
Astrup A
Eur J Clin Nutr; 2024 Jun; ():. PubMed ID: 38890501
[TBL] [Abstract][Full Text] [Related]
2. EndoBarrier gastrointestinal liner. Delineation of underlying mechanisms and clinical effects.
Rohde U
Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808040
[TBL] [Abstract][Full Text] [Related]
3. Effect of dietary macronutrients on postprandial incretin hormone release and satiety in obese and normal-weight women.
Wikarek T; Chudek J; Owczarek A; Olszanecka-Glinianowicz M
Br J Nutr; 2014 Jan; 111(2):236-46. PubMed ID: 23920407
[TBL] [Abstract][Full Text] [Related]
4. The role of postprandial releases of insulin and incretin hormones in meal-induced satiety--effect of obesity and weight reduction.
Verdich C; Toubro S; Buemann B; Lysgård Madsen J; Juul Holst J; Astrup A
Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1206-14. PubMed ID: 11477506
[TBL] [Abstract][Full Text] [Related]
5. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.
Madsbad S
Diabetes Obes Metab; 2014 Jan; 16(1):9-21. PubMed ID: 23617798
[TBL] [Abstract][Full Text] [Related]
6. A Pilot Study Examining the Effects of GLP-1 Receptor Blockade Using Exendin-(9,39) on Gastric Emptying and Caloric Intake in Subjects With and Without Bariatric Surgery.
Kittah E; Camilleri M; Jensen MD; Vella A
Metab Syndr Relat Disord; 2020 Nov; 18(9):406-412. PubMed ID: 32833560
[No Abstract] [Full Text] [Related]
7. Weight loss did not modify macronutrient specific response of hormones and satiety in overweight and obese people without metabolic disease - results from a clinical trial.
Li L; Decker AM; Stobäus N; Beer F; Grittner U; Spranger J; Mai K
Clin Nutr; 2022 Apr; 41(4):948-957. PubMed ID: 35303516
[TBL] [Abstract][Full Text] [Related]
8. Incretin hormones and type 2 diabetes.
Nauck MA; Müller TD
Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.
Näslund E; Gutniak M; Skogar S; Rössner S; Hellström PM
Am J Clin Nutr; 1998 Sep; 68(3):525-30. PubMed ID: 9734726
[TBL] [Abstract][Full Text] [Related]
10. Discovery of the GI Effects of GLP-1: An Historical Perspective.
Holst JJ
Dig Dis Sci; 2022 Jul; 67(7):2716-2720. PubMed ID: 35635627
[TBL] [Abstract][Full Text] [Related]
11. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide analogues for type 2 diabetes mellitus.
Shyangdan DS; Royle P; Clar C; Sharma P; Waugh N; Snaith A
Cochrane Database Syst Rev; 2011 Oct; 2011(10):CD006423. PubMed ID: 21975753
[TBL] [Abstract][Full Text] [Related]
13. Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial.
Kuwata H; Iwasaki M; Shimizu S; Minami K; Maeda H; Seino S; Nakada K; Nosaka C; Murotani K; Kurose T; Seino Y; Yabe D
Diabetologia; 2016 Mar; 59(3):453-61. PubMed ID: 26704625
[TBL] [Abstract][Full Text] [Related]
14. The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials.
Aldawsari M; Almadani FA; Almuhammadi N; Algabsani S; Alamro Y; Aldhwayan M
Diabetes Metab Syndr Obes; 2023; 16():575-595. PubMed ID: 36890965
[TBL] [Abstract][Full Text] [Related]
15. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
16. Effects of carbohydrate restriction on postprandial glucose metabolism,
Skytte MJ; Samkani A; Astrup A; Frystyk J; Rehfeld JF; Holst JJ; Madsbad S; Burling K; Fenger M; Thomsen MN; Larsen TM; Krarup T; Haugaard SB
Am J Physiol Endocrinol Metab; 2021 Jan; 320(1):E7-E18. PubMed ID: 33103448
[TBL] [Abstract][Full Text] [Related]
17. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
[TBL] [Abstract][Full Text] [Related]
18. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
Gallwitz B
Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
[TBL] [Abstract][Full Text] [Related]
19. The role of gastric function in control of food intake (and body weight) in relation to obesity, as well as pharmacological and surgical interventions.
Camilleri M
Neurogastroenterol Motil; 2024 Feb; 36(2):e14660. PubMed ID: 37638839
[TBL] [Abstract][Full Text] [Related]
20. The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond.
João AL; Reis F; Fernandes R
Obes Rev; 2016 Jul; 17(7):553-72. PubMed ID: 27125902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
